The full content of Annals is available to subscribers

Subscribe/Learn More  >
Brief Reports |

Interferon-α for the Hypereosinophilic Syndrome

Robert M. Zielinski, MD; and William D. Lawrence, MD
[+] Article, Author, and Disclosure Information

Requests for Reprints: William D. Lawrence, MD, Century Medical Associates, 1616 Kensington Avenue, Buffalo, NY 14215.

Current Author Addresses: Dr. Zielinski: Department of Medicine, Buffalo Veterans Affairs Medical Center, 3495 Bailey Avenue, Buffalo, NY 14215.

Dr. Lawrence: Century Medical Associates, 1616 Kensington Avenue, Buffalo, NY 14215.

Ann Intern Med. 1990;113(9):716-718. doi:10.7326/0003-4819-113-9-716
Text Size: A A A
This excerpt has been provided in the absence of an abstract.

The hypereosinophilic syndrome is defined by unexplained eosinophilia (eosinophil count > 1.5 x 109/L) lasting more than 6 months (1). Characteristic clinical features include congestive heart failure with endocardial fibrosis (2), venous and arterial thromboembolism, neuropsychiatric dysfunction (3), anemia, and thrombocytopenia. These disease manifestations have been attributed to tissue infiltration by eosinophils and the direct toxic effects of the products of eosinophilic granules (1, 2, 4).

Therapy has been directed at lowering the absolute eosinophil count to below 1 x 109/L with prednisone and the cytotoxic agent, hydroxyurea (1, 5). This therapeutic approach appears to have dramatically improved median survival


First Page Preview

View Large
First page PDF preview





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $42.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Related Point of Care
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.